nodes	percent_of_prediction	percent_of_DWPC	metapath
Plerixafor—CXCR4—Hematopoietic Stem Cell Differentiation—EPO—thyroid cancer	0.0352	0.0877	CbGpPWpGaD
Plerixafor—Platelet count decreased—Vandetanib—thyroid cancer	0.0328	0.0579	CcSEcCtD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—CP—thyroid cancer	0.03	0.0749	CbGpPWpGaD
Plerixafor—CXCR4—Peptide GPCRs—TSHR—thyroid cancer	0.0274	0.0684	CbGpPWpGaD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—EPO—thyroid cancer	0.0236	0.0588	CbGpPWpGaD
Plerixafor—Haematoma—Sorafenib—thyroid cancer	0.0209	0.0369	CcSEcCtD
Plerixafor—CXCR4—Cardiac Progenitor Differentiation—NRG1—thyroid cancer	0.0195	0.0486	CbGpPWpGaD
Plerixafor—CXCR4—HIV Life Cycle—TPR—thyroid cancer	0.0168	0.042	CbGpPWpGaD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—TERT—thyroid cancer	0.0147	0.0366	CbGpPWpGaD
Plerixafor—CXCR4—GPCR ligand binding—CALCB—thyroid cancer	0.0142	0.0355	CbGpPWpGaD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—HIF1A—thyroid cancer	0.014	0.035	CbGpPWpGaD
Plerixafor—CXCR4—HIV Infection—TPR—thyroid cancer	0.0116	0.029	CbGpPWpGaD
Plerixafor—CXCR4—trachea—thyroid cancer	0.0107	0.335	CbGeAlD
Plerixafor—CXCR4—S1P3 pathway—AKT1—thyroid cancer	0.0103	0.0256	CbGpPWpGaD
Plerixafor—CXCR4—Peptide ligand-binding receptors—SST—thyroid cancer	0.01	0.025	CbGpPWpGaD
Plerixafor—Haemoglobin—Vandetanib—thyroid cancer	0.00985	0.0174	CcSEcCtD
Plerixafor—Haemorrhage—Vandetanib—thyroid cancer	0.0098	0.0173	CcSEcCtD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—TSHR—thyroid cancer	0.00864	0.0216	CbGpPWpGaD
Plerixafor—Mental disorder—Vandetanib—thyroid cancer	0.00859	0.0151	CcSEcCtD
Plerixafor—CXCR4—G alpha (i) signalling events—SST—thyroid cancer	0.00846	0.0211	CbGpPWpGaD
Plerixafor—CXCR4—thyroid gland—thyroid cancer	0.00845	0.265	CbGeAlD
Plerixafor—CXCR4—GPCR downstream signaling—CALCB—thyroid cancer	0.00804	0.02	CbGpPWpGaD
Plerixafor—Abdominal discomfort—Sorafenib—thyroid cancer	0.00792	0.014	CcSEcCtD
Plerixafor—Loss of consciousness—Vandetanib—thyroid cancer	0.0075	0.0132	CcSEcCtD
Plerixafor—CXCR4—head—thyroid cancer	0.0075	0.235	CbGeAlD
Plerixafor—CXCR4—Signaling by GPCR—CALCB—thyroid cancer	0.0073	0.0182	CbGpPWpGaD
Plerixafor—Arthralgia—Vandetanib—thyroid cancer	0.00726	0.0128	CcSEcCtD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.00721	0.0127	CcSEcCtD
Plerixafor—Dry mouth—Vandetanib—thyroid cancer	0.00711	0.0125	CcSEcCtD
Plerixafor—Nervous system disorder—Vandetanib—thyroid cancer	0.00683	0.012	CcSEcCtD
Plerixafor—Skin disorder—Vandetanib—thyroid cancer	0.00676	0.0119	CcSEcCtD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—SST—thyroid cancer	0.00672	0.0168	CbGpPWpGaD
Plerixafor—Haemoglobin—Sorafenib—thyroid cancer	0.00665	0.0117	CcSEcCtD
Plerixafor—Haemorrhage—Sorafenib—thyroid cancer	0.00661	0.0117	CcSEcCtD
Plerixafor—CXCR4—GPCR ligand binding—TSHR—thyroid cancer	0.00658	0.0164	CbGpPWpGaD
Plerixafor—CXCR4—Disease—TRIM24—thyroid cancer	0.00655	0.0163	CbGpPWpGaD
Plerixafor—Connective tissue disorder—Sorafenib—thyroid cancer	0.0065	0.0115	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.00635	0.0112	CcSEcCtD
Plerixafor—Insomnia—Vandetanib—thyroid cancer	0.0063	0.0111	CcSEcCtD
Plerixafor—Paraesthesia—Vandetanib—thyroid cancer	0.00625	0.011	CcSEcCtD
Plerixafor—Dyspnoea—Vandetanib—thyroid cancer	0.00621	0.0109	CcSEcCtD
Plerixafor—CXCR4—Disease—CHST14—thyroid cancer	0.00616	0.0154	CbGpPWpGaD
Plerixafor—Dyspepsia—Vandetanib—thyroid cancer	0.00613	0.0108	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00601	0.0106	CcSEcCtD
Plerixafor—Fatigue—Vandetanib—thyroid cancer	0.006	0.0106	CcSEcCtD
Plerixafor—Immune system disorder—Sorafenib—thyroid cancer	0.00597	0.0105	CcSEcCtD
Plerixafor—Constipation—Vandetanib—thyroid cancer	0.00596	0.0105	CcSEcCtD
Plerixafor—Pain—Vandetanib—thyroid cancer	0.00596	0.0105	CcSEcCtD
Plerixafor—CXCR4—Disease—TRIM33—thyroid cancer	0.00584	0.0146	CbGpPWpGaD
Plerixafor—Mental disorder—Sorafenib—thyroid cancer	0.00579	0.0102	CcSEcCtD
Plerixafor—Erythema—Sorafenib—thyroid cancer	0.00576	0.0101	CcSEcCtD
Plerixafor—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00569	0.01	CcSEcCtD
Plerixafor—CXCR4—GPCR ligand binding—PTCH1—thyroid cancer	0.0056	0.014	CbGpPWpGaD
Plerixafor—Abdominal pain—Vandetanib—thyroid cancer	0.00551	0.00971	CcSEcCtD
Plerixafor—CXCR4—lymph node—thyroid cancer	0.00525	0.165	CbGeAlD
Plerixafor—Syncope—Sorafenib—thyroid cancer	0.00516	0.0091	CcSEcCtD
Plerixafor—CXCR4—GPCR ligand binding—SST—thyroid cancer	0.00512	0.0128	CbGpPWpGaD
Plerixafor—Loss of consciousness—Sorafenib—thyroid cancer	0.00506	0.00892	CcSEcCtD
Plerixafor—Inflammation—Epirubicin—thyroid cancer	0.00502	0.00884	CcSEcCtD
Plerixafor—Asthenia—Vandetanib—thyroid cancer	0.005	0.00881	CcSEcCtD
Plerixafor—CXCR4—GPCR ligand binding—CALCA—thyroid cancer	0.00493	0.0123	CbGpPWpGaD
Plerixafor—Pruritus—Vandetanib—thyroid cancer	0.00493	0.00869	CcSEcCtD
Plerixafor—Musculoskeletal pain—Epirubicin—thyroid cancer	0.00493	0.00868	CcSEcCtD
Plerixafor—Arthralgia—Sorafenib—thyroid cancer	0.0049	0.00864	CcSEcCtD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.00487	0.00858	CcSEcCtD
Plerixafor—Injection site reaction—Epirubicin—thyroid cancer	0.00484	0.00853	CcSEcCtD
Plerixafor—Dry mouth—Sorafenib—thyroid cancer	0.00479	0.00845	CcSEcCtD
Plerixafor—Diarrhoea—Vandetanib—thyroid cancer	0.00477	0.0084	CcSEcCtD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—AKT1—thyroid cancer	0.00472	0.0118	CbGpPWpGaD
Plerixafor—Anaphylactic shock—Sorafenib—thyroid cancer	0.0047	0.00828	CcSEcCtD
Plerixafor—Inflammation—Doxorubicin—thyroid cancer	0.00464	0.00818	CcSEcCtD
Plerixafor—Shock—Sorafenib—thyroid cancer	0.00462	0.00815	CcSEcCtD
Plerixafor—Nervous system disorder—Sorafenib—thyroid cancer	0.00461	0.00812	CcSEcCtD
Plerixafor—Dizziness—Vandetanib—thyroid cancer	0.00461	0.00812	CcSEcCtD
Plerixafor—Skin disorder—Sorafenib—thyroid cancer	0.00456	0.00805	CcSEcCtD
Plerixafor—Musculoskeletal pain—Doxorubicin—thyroid cancer	0.00456	0.00803	CcSEcCtD
Plerixafor—Injection site reaction—Doxorubicin—thyroid cancer	0.00448	0.00789	CcSEcCtD
Plerixafor—Vomiting—Vandetanib—thyroid cancer	0.00443	0.00781	CcSEcCtD
Plerixafor—Rash—Vandetanib—thyroid cancer	0.00439	0.00774	CcSEcCtD
Plerixafor—Dermatitis—Vandetanib—thyroid cancer	0.00439	0.00773	CcSEcCtD
Plerixafor—Headache—Vandetanib—thyroid cancer	0.00436	0.00769	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—CALCB—thyroid cancer	0.00431	0.0108	CbGpPWpGaD
Plerixafor—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.00428	0.00755	CcSEcCtD
Plerixafor—Dyspnoea—Sorafenib—thyroid cancer	0.00419	0.00738	CcSEcCtD
Plerixafor—Nausea—Vandetanib—thyroid cancer	0.00414	0.00729	CcSEcCtD
Plerixafor—Dyspepsia—Sorafenib—thyroid cancer	0.00414	0.00729	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—TRIM33—thyroid cancer	0.00409	0.0102	CbGpPWpGaD
Plerixafor—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00406	0.00715	CcSEcCtD
Plerixafor—Fatigue—Sorafenib—thyroid cancer	0.00405	0.00714	CcSEcCtD
Plerixafor—Constipation—Sorafenib—thyroid cancer	0.00402	0.00708	CcSEcCtD
Plerixafor—Pain—Sorafenib—thyroid cancer	0.00402	0.00708	CcSEcCtD
Plerixafor—CXCR4—Disease—TCF7L1—thyroid cancer	0.00389	0.00971	CbGpPWpGaD
Plerixafor—CXCR4—CXCR4-mediated signaling events—AKT1—thyroid cancer	0.00389	0.0097	CbGpPWpGaD
Plerixafor—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00384	0.00677	CcSEcCtD
Plerixafor—Urticaria—Sorafenib—thyroid cancer	0.00373	0.00658	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—TSHR—thyroid cancer	0.00372	0.00928	CbGpPWpGaD
Plerixafor—Abdominal pain—Sorafenib—thyroid cancer	0.00371	0.00655	CcSEcCtD
Plerixafor—Hypersensitivity—Sorafenib—thyroid cancer	0.00346	0.0061	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—TSHR—thyroid cancer	0.00338	0.00843	CbGpPWpGaD
Plerixafor—Asthenia—Sorafenib—thyroid cancer	0.00337	0.00594	CcSEcCtD
Plerixafor—Pruritus—Sorafenib—thyroid cancer	0.00332	0.00586	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—PRKAR1A—thyroid cancer	0.00332	0.00829	CbGpPWpGaD
Plerixafor—Orthostatic hypotension—Epirubicin—thyroid cancer	0.00323	0.00569	CcSEcCtD
Plerixafor—Diarrhoea—Sorafenib—thyroid cancer	0.00321	0.00567	CcSEcCtD
Plerixafor—Dizziness—Sorafenib—thyroid cancer	0.00311	0.00548	CcSEcCtD
Plerixafor—Abdominal distension—Epirubicin—thyroid cancer	0.00307	0.00542	CcSEcCtD
Plerixafor—Vomiting—Sorafenib—thyroid cancer	0.00299	0.00527	CcSEcCtD
Plerixafor—Orthostatic hypotension—Doxorubicin—thyroid cancer	0.00299	0.00526	CcSEcCtD
Plerixafor—Rash—Sorafenib—thyroid cancer	0.00296	0.00522	CcSEcCtD
Plerixafor—Dermatitis—Sorafenib—thyroid cancer	0.00296	0.00522	CcSEcCtD
Plerixafor—Headache—Sorafenib—thyroid cancer	0.00294	0.00519	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—SST—thyroid cancer	0.00289	0.00722	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—PTCH1—thyroid cancer	0.00287	0.00717	CbGpPWpGaD
Plerixafor—CXCR4—Disease—TPR—thyroid cancer	0.00285	0.00711	CbGpPWpGaD
Plerixafor—Abdominal distension—Doxorubicin—thyroid cancer	0.00284	0.00501	CcSEcCtD
Plerixafor—CXCR4—Disease—PRKAR1A—thyroid cancer	0.0028	0.00699	CbGpPWpGaD
Plerixafor—Nausea—Sorafenib—thyroid cancer	0.00279	0.00492	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—CALCA—thyroid cancer	0.00278	0.00695	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—TCF7L1—thyroid cancer	0.00273	0.0068	CbGpPWpGaD
Plerixafor—CXCR4—Disease—MEN1—thyroid cancer	0.00268	0.00668	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—SST—thyroid cancer	0.00263	0.00655	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—CALCA—thyroid cancer	0.00253	0.00631	CbGpPWpGaD
Plerixafor—Haemoglobin—Epirubicin—thyroid cancer	0.00246	0.00433	CcSEcCtD
Plerixafor—Haemorrhage—Epirubicin—thyroid cancer	0.00244	0.00431	CcSEcCtD
Plerixafor—Connective tissue disorder—Epirubicin—thyroid cancer	0.0024	0.00423	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—CDK1—thyroid cancer	0.00229	0.00571	CbGpPWpGaD
Plerixafor—Haemoglobin—Doxorubicin—thyroid cancer	0.00227	0.00401	CcSEcCtD
Plerixafor—Haemorrhage—Doxorubicin—thyroid cancer	0.00226	0.00399	CcSEcCtD
Plerixafor—Connective tissue disorder—Doxorubicin—thyroid cancer	0.00222	0.00392	CcSEcCtD
Plerixafor—Immune system disorder—Epirubicin—thyroid cancer	0.00221	0.00389	CcSEcCtD
Plerixafor—Mental disorder—Epirubicin—thyroid cancer	0.00214	0.00377	CcSEcCtD
Plerixafor—CXCR4—Disease—CALCA—thyroid cancer	0.00213	0.00532	CbGpPWpGaD
Plerixafor—Erythema—Epirubicin—thyroid cancer	0.00213	0.00375	CcSEcCtD
Plerixafor—Flatulence—Epirubicin—thyroid cancer	0.0021	0.0037	CcSEcCtD
Plerixafor—Immune system disorder—Doxorubicin—thyroid cancer	0.00204	0.0036	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—TSHR—thyroid cancer	0.002	0.00498	CbGpPWpGaD
Plerixafor—Mental disorder—Doxorubicin—thyroid cancer	0.00198	0.00349	CcSEcCtD
Plerixafor—Ill-defined disorder—Epirubicin—thyroid cancer	0.00197	0.00348	CcSEcCtD
Plerixafor—Erythema—Doxorubicin—thyroid cancer	0.00197	0.00347	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—PRKAR1A—thyroid cancer	0.00196	0.0049	CbGpPWpGaD
Plerixafor—Flatulence—Doxorubicin—thyroid cancer	0.00194	0.00342	CcSEcCtD
Plerixafor—CXCR4—Disease—CDK1—thyroid cancer	0.00193	0.00482	CbGpPWpGaD
Plerixafor—Malaise—Epirubicin—thyroid cancer	0.00192	0.00338	CcSEcCtD
Plerixafor—Syncope—Epirubicin—thyroid cancer	0.00191	0.00336	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—MEN1—thyroid cancer	0.00188	0.00468	CbGpPWpGaD
Plerixafor—Loss of consciousness—Epirubicin—thyroid cancer	0.00187	0.0033	CcSEcCtD
Plerixafor—Ill-defined disorder—Doxorubicin—thyroid cancer	0.00183	0.00322	CcSEcCtD
Plerixafor—Arthralgia—Epirubicin—thyroid cancer	0.00181	0.00319	CcSEcCtD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.0018	0.00317	CcSEcCtD
Plerixafor—Discomfort—Epirubicin—thyroid cancer	0.00179	0.00315	CcSEcCtD
Plerixafor—Malaise—Doxorubicin—thyroid cancer	0.00178	0.00313	CcSEcCtD
Plerixafor—Dry mouth—Epirubicin—thyroid cancer	0.00177	0.00312	CcSEcCtD
Plerixafor—Syncope—Doxorubicin—thyroid cancer	0.00177	0.00311	CcSEcCtD
Plerixafor—Anaphylactic shock—Epirubicin—thyroid cancer	0.00174	0.00306	CcSEcCtD
Plerixafor—Loss of consciousness—Doxorubicin—thyroid cancer	0.00173	0.00305	CcSEcCtD
Plerixafor—Shock—Epirubicin—thyroid cancer	0.00171	0.00301	CcSEcCtD
Plerixafor—Nervous system disorder—Epirubicin—thyroid cancer	0.0017	0.003	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—PTCH1—thyroid cancer	0.0017	0.00423	CbGpPWpGaD
Plerixafor—Skin disorder—Epirubicin—thyroid cancer	0.00169	0.00297	CcSEcCtD
Plerixafor—Hyperhidrosis—Epirubicin—thyroid cancer	0.00168	0.00296	CcSEcCtD
Plerixafor—Arthralgia—Doxorubicin—thyroid cancer	0.00168	0.00295	CcSEcCtD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.00166	0.00293	CcSEcCtD
Plerixafor—Discomfort—Doxorubicin—thyroid cancer	0.00166	0.00292	CcSEcCtD
Plerixafor—Dry mouth—Doxorubicin—thyroid cancer	0.00164	0.00289	CcSEcCtD
Plerixafor—Anaphylactic shock—Doxorubicin—thyroid cancer	0.00161	0.00283	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.00158	0.00279	CcSEcCtD
Plerixafor—Shock—Doxorubicin—thyroid cancer	0.00158	0.00279	CcSEcCtD
Plerixafor—Nervous system disorder—Doxorubicin—thyroid cancer	0.00158	0.00278	CcSEcCtD
Plerixafor—Insomnia—Epirubicin—thyroid cancer	0.00157	0.00277	CcSEcCtD
Plerixafor—Skin disorder—Doxorubicin—thyroid cancer	0.00156	0.00275	CcSEcCtD
Plerixafor—Paraesthesia—Epirubicin—thyroid cancer	0.00156	0.00275	CcSEcCtD
Plerixafor—Hyperhidrosis—Doxorubicin—thyroid cancer	0.00155	0.00274	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—SST—thyroid cancer	0.00155	0.00387	CbGpPWpGaD
Plerixafor—CXCR4—Disease—NRG1—thyroid cancer	0.00155	0.00387	CbGpPWpGaD
Plerixafor—Dyspnoea—Epirubicin—thyroid cancer	0.00155	0.00273	CcSEcCtD
Plerixafor—Dyspepsia—Epirubicin—thyroid cancer	0.00153	0.00269	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.0015	0.00264	CcSEcCtD
Plerixafor—Fatigue—Epirubicin—thyroid cancer	0.0015	0.00264	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—CALCA—thyroid cancer	0.00149	0.00373	CbGpPWpGaD
Plerixafor—Pain—Epirubicin—thyroid cancer	0.00148	0.00262	CcSEcCtD
Plerixafor—Constipation—Epirubicin—thyroid cancer	0.00148	0.00262	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.00146	0.00258	CcSEcCtD
Plerixafor—Insomnia—Doxorubicin—thyroid cancer	0.00145	0.00256	CcSEcCtD
Plerixafor—Paraesthesia—Doxorubicin—thyroid cancer	0.00144	0.00254	CcSEcCtD
Plerixafor—Dyspnoea—Doxorubicin—thyroid cancer	0.00143	0.00253	CcSEcCtD
Plerixafor—Feeling abnormal—Epirubicin—thyroid cancer	0.00143	0.00252	CcSEcCtD
Plerixafor—Gastrointestinal pain—Epirubicin—thyroid cancer	0.00142	0.0025	CcSEcCtD
Plerixafor—Dyspepsia—Doxorubicin—thyroid cancer	0.00141	0.00249	CcSEcCtD
Plerixafor—CXCR4—Disease—TERT—thyroid cancer	0.00139	0.00347	CbGpPWpGaD
Plerixafor—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.00139	0.00245	CcSEcCtD
Plerixafor—Fatigue—Doxorubicin—thyroid cancer	0.00139	0.00244	CcSEcCtD
Plerixafor—Urticaria—Epirubicin—thyroid cancer	0.00138	0.00243	CcSEcCtD
Plerixafor—Pain—Doxorubicin—thyroid cancer	0.00137	0.00242	CcSEcCtD
Plerixafor—Constipation—Doxorubicin—thyroid cancer	0.00137	0.00242	CcSEcCtD
Plerixafor—Abdominal pain—Epirubicin—thyroid cancer	0.00137	0.00242	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—CDK1—thyroid cancer	0.00135	0.00337	CbGpPWpGaD
Plerixafor—CXCR4—Disease—HIF1A—thyroid cancer	0.00133	0.00332	CbGpPWpGaD
Plerixafor—Feeling abnormal—Doxorubicin—thyroid cancer	0.00132	0.00233	CcSEcCtD
Plerixafor—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.00131	0.00232	CcSEcCtD
Plerixafor—Hypersensitivity—Epirubicin—thyroid cancer	0.00128	0.00226	CcSEcCtD
Plerixafor—Urticaria—Doxorubicin—thyroid cancer	0.00128	0.00225	CcSEcCtD
Plerixafor—Abdominal pain—Doxorubicin—thyroid cancer	0.00127	0.00224	CcSEcCtD
Plerixafor—Asthenia—Epirubicin—thyroid cancer	0.00125	0.0022	CcSEcCtD
Plerixafor—Pruritus—Epirubicin—thyroid cancer	0.00123	0.00217	CcSEcCtD
Plerixafor—Diarrhoea—Epirubicin—thyroid cancer	0.00119	0.00209	CcSEcCtD
Plerixafor—Hypersensitivity—Doxorubicin—thyroid cancer	0.00118	0.00209	CcSEcCtD
Plerixafor—Asthenia—Doxorubicin—thyroid cancer	0.00115	0.00203	CcSEcCtD
Plerixafor—Dizziness—Epirubicin—thyroid cancer	0.00115	0.00202	CcSEcCtD
Plerixafor—Pruritus—Doxorubicin—thyroid cancer	0.00114	0.002	CcSEcCtD
Plerixafor—Vomiting—Epirubicin—thyroid cancer	0.0011	0.00195	CcSEcCtD
Plerixafor—CXCR4—Disease—BRAF—thyroid cancer	0.0011	0.00275	CbGpPWpGaD
Plerixafor—Diarrhoea—Doxorubicin—thyroid cancer	0.0011	0.00194	CcSEcCtD
Plerixafor—Rash—Epirubicin—thyroid cancer	0.00109	0.00193	CcSEcCtD
Plerixafor—Dermatitis—Epirubicin—thyroid cancer	0.00109	0.00193	CcSEcCtD
Plerixafor—Headache—Epirubicin—thyroid cancer	0.00109	0.00192	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—NRG1—thyroid cancer	0.00109	0.00271	CbGpPWpGaD
Plerixafor—Dizziness—Doxorubicin—thyroid cancer	0.00106	0.00187	CcSEcCtD
Plerixafor—Nausea—Epirubicin—thyroid cancer	0.00103	0.00182	CcSEcCtD
Plerixafor—Vomiting—Doxorubicin—thyroid cancer	0.00102	0.0018	CcSEcCtD
Plerixafor—Rash—Doxorubicin—thyroid cancer	0.00101	0.00179	CcSEcCtD
Plerixafor—Dermatitis—Doxorubicin—thyroid cancer	0.00101	0.00178	CcSEcCtD
Plerixafor—Headache—Doxorubicin—thyroid cancer	0.00101	0.00177	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—TERT—thyroid cancer	0.000975	0.00243	CbGpPWpGaD
Plerixafor—Nausea—Doxorubicin—thyroid cancer	0.000954	0.00168	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—HIF1A—thyroid cancer	0.000932	0.00233	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PTGS2—thyroid cancer	0.00089	0.00222	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—NRAS—thyroid cancer	0.000821	0.00205	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PTEN—thyroid cancer	0.000776	0.00194	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—BRAF—thyroid cancer	0.000772	0.00193	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—KRAS—thyroid cancer	0.000707	0.00176	CbGpPWpGaD
Plerixafor—CXCR4—Disease—NRAS—thyroid cancer	0.000693	0.00173	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—HRAS—thyroid cancer	0.000601	0.0015	CbGpPWpGaD
Plerixafor—CXCR4—Disease—KRAS—thyroid cancer	0.000596	0.00149	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—AKT1—thyroid cancer	0.000584	0.00146	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CCND1—thyroid cancer	0.000563	0.00141	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PTEN—thyroid cancer	0.000544	0.00136	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—AKT1—thyroid cancer	0.00053	0.00132	CbGpPWpGaD
Plerixafor—CXCR4—Disease—HRAS—thyroid cancer	0.000507	0.00126	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—NRAS—thyroid cancer	0.000485	0.00121	CbGpPWpGaD
Plerixafor—CXCR4—Disease—AKT1—thyroid cancer	0.000447	0.00112	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—KRAS—thyroid cancer	0.000418	0.00104	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—TP53—thyroid cancer	0.000371	0.000926	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—HRAS—thyroid cancer	0.000355	0.000885	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—AKT1—thyroid cancer	0.000313	0.000782	CbGpPWpGaD
